Xeomin for Miami Beach Patients: A Practical Guide to Treatment in Aventura

Xeomin for Miami Beach Patients: A Practical Guide to Treatment in Aventura

Xeomin is the brand name for incobotulinumtoxinA, a botulinum toxin type A prescription product. The current FDA prescribing information includes temporary improvement of moderate-to-severe glabellar lines, horizontal forehead lines and lateral canthal lines in adults. It is one of the neurotoxins offered at Lumini Medical Spa in Aventura Mall.

For a patient traveling from Miami Beach, the important questions are not whether Xeomin is “stronger” or “purer” than another brand. The useful questions are whether the expression lines are caused by muscles that should be treated, which areas require balancing, how many Xeomin-specific units fit the anatomy and whether the medical history makes treatment appropriate.

Xeomin can temporarily soften selected upper-face expression lines by blocking acetylcholine release at the neuromuscular junction. Results develop over days rather than instantly and vary by patient. The FDA label states that Xeomin potency units cannot be compared with or converted into units of another botulinum toxin product, and retreatment should occur no more frequently than every three months.

Lumini’s published Xeomin price is $15 per Xeomin unit. The total depends on the areas treated and the individualized dose; a consultation is necessary before an accurate treatment total can be calculated.

The current U.S. prescribing information covers the temporary improvement of three upper-face patterns in adults:

• moderate-to-severe glabellar lines associated with corrugator and procerus activity;
• moderate-to-severe horizontal forehead lines associated with frontalis activity; and
• moderate-to-severe lateral canthal lines associated with orbicularis oculi activity.

Botulinum toxin products use product-specific biological assays. The FDA label explicitly states that Xeomin units cannot be compared with or converted into units of another botulinum toxin. A chart that treats one Xeomin unit as a fixed number of Botox or Dysport units would therefore conflict with the prescribing information.

This is also why price-per-unit comparisons must remain product-specific. Lumini lists Botox at $18 per Botox unit, Dysport at $15 per Lumini treatment unit and Xeomin at $15 per Xeomin unit, but those posted numbers are not a pharmacologic conversion table.

Randomized, double-blind, placebo-controlled phase III studies support incobotulinumtoxinA for upper facial lines. Two recent trials enrolled 362 and 368 adults and evaluated simultaneous treatment of glabellar, horizontal forehead and lateral canthal lines. Primary and secondary efficacy endpoints favored incobotulinumtoxinA over placebo, without a new safety signal.

A 2026 systematic review and meta-analysis included three randomized trials with 704 participants. It found higher day-30 response rates than placebo across the three upper-face areas. The authors also emphasized the need for more long-term evidence. These data support temporary improvement; they do not justify guaranteeing a specific duration or an identical result for every patient.

Xeomin does not work at the moment of injection. Neuromuscular effect develops over the following days, and the clinical result should be assessed after it has had time to settle. Duration varies with dose, muscle activity, anatomy, prior treatment history and individual response.

The FDA label sets a clear safety boundary: cosmetic retreatment should be administered no more frequently than every three months. A patient should not schedule early redosing simply because movement remains before the planned assessment.

Xeomin is contraindicated in patients with known hypersensitivity to botulinum neurotoxin type A or the product’s excipients and when infection is present at a proposed injection site.

Expected local reactions can include injection-site bruising. Depending on the area and pattern treated, unwanted weakness may produce asymmetry or eyelid or brow ptosis. The label also warns about interactions with aminoglycosides and other agents that interfere with neuromuscular transmission, anticholinergic drugs, muscle relaxants and other botulinum toxin products.

Xeomin carries the boxed warning shared by botulinum toxin products: effects can spread from the injection area and produce generalized weakness, double or blurred vision, ptosis, swallowing or speech difficulty, urinary incontinence or breathing problems hours to weeks after treatment. Swallowing and breathing problems can be life-threatening. Any such symptoms require immediate medical attention.

Tell the provider about pregnancy, breastfeeding, neuromuscular disease, swallowing or breathing problems, prior facial surgery, medications and every botulinum toxin treatment received in recent months.

Lumini is inside Aventura Mall at 19565 Biscayne Boulevard, Suite 1954. A Miami Beach patient should allow for variable traffic rather than scheduling around a guaranteed drive time. The visit includes facial assessment, medical screening, treatment planning and consent before any injection.

Avoid treating the appointment as a quick commodity purchase based only on a requested unit count. The provider may recommend treating a connected muscle group, reducing the proposed dose, postponing treatment or choosing another plan to preserve expression and brow balance.

Is Xeomin FDA-approved for forehead lines and crow’s feet?

Yes. Current U.S. prescribing information includes moderate-to-severe horizontal forehead lines and lateral canthal lines, as well as glabellar lines, in adults.

Is Xeomin the same as Botox or Dysport?

No. All are botulinum toxin type A products, but they are separate preparations with product-specific assays and labels. Xeomin units cannot be converted into units of another botulinum toxin product.

How much is Xeomin at Lumini?

Lumini’s published price is $15 per Xeomin unit. The total depends on the Xeomin-specific dose and areas selected after assessment.

How soon can Xeomin be repeated?

The FDA label states that Xeomin retreatment for upper facial lines should occur no more frequently than every three months.

Will Xeomin freeze my face?

That is not the objective of an individualized plan. Dose and placement are selected to soften targeted muscle activity while managing brow position, asymmetry and the patient’s preference for movement. Results still vary.

Who should not receive Xeomin?

Do not receive it with a known hypersensitivity to botulinum neurotoxin type A or its excipients, or when an intended injection site is infected. Other medical conditions and medicines may require postponement or a different plan.

What symptoms require urgent attention?

Seek immediate medical care for swallowing, speaking or breathing difficulty, generalized weakness, double or blurred vision or other symptoms consistent with spread of toxin effect.

1. U.S. Food and Drug Administration. XEOMIN (incobotulinumtoxinA) Prescribing Information. BLA 125360/S-110. Revised February 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125360s110lbl.pdf
2. Joseph J, Sudimac V, Mersmann S, Kerscher M. IncobotulinumtoxinA in the treatment of upper facial lines: results from two randomized, double-blind, placebo-controlled, phase III studies. Aesthetic Surgery Journal. 2025;45(3):293-304. PMID: 39475143. https://pubmed.ncbi.nlm.nih.gov/39475143/
3. Kerscher M, Rzany B, Prager W, Turnbull C, Trevidic P, Inglefield C. Efficacy and safety of incobotulinumtoxinA in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase III study. Dermatologic Surgery. 2015;41(10):1149-1157. PMID: 26359996. https://pubmed.ncbi.nlm.nih.gov/26359996/
4. Azam MT, Azam MH, Azam MH, Ashraf S, Khan MA, Aminpoor H. Efficacy and safety of incobotulinumtoxinA for the simultaneous treatment of upper facial lines: a GRADE-assessed systematic review and meta-analysis. Aesthetic Surgery Journal Open Forum. 2026;8:ojag085. PMID: 42291577. https://pubmed.ncbi.nlm.nih.gov/42291577/
5. Lumini Medical Spa. Med Spa Pricing in Aventura. Accessed August 26, 2026. https://luminimedspa.com/med-spa-pricing-aventura/

Medically reviewed by Dr. Caio Trentin, M.D., Physician, Lumini Medical Spa. Educational information only. It does not replace an in-person assessment. Individual results vary.